切换至 "中华医学电子期刊资源库"

中华危重症医学杂志(电子版) ›› 2016, Vol. 09 ›› Issue (03) : 159 -162. doi: 10.3877/cma.j.issn.1674-6880.2016.03.004

所属专题: 文献

论著

重症肺炎患者血清胆碱酯酶含量变化及其与急性病生理学和长期健康评价Ⅱ评分、多器官功能障碍综合征评分的相关性研究
莫新1, 梁艳冰2, 陈志斌2, 李振宇2, 杨冰玉1, 马中富2,()   
  1. 1. 528000 广东佛山,佛山市第三人民医院神经内科
    2. 510080 广东广州,中山大学附属第一医院普内科
  • 收稿日期:2015-11-19 出版日期:2016-06-01
  • 通信作者: 马中富
  • 基金资助:
    广东省佛山市医学类科技攻关项目(2015AB00384)

Correlation of serum cholinesterase and acute physiology and chronic health evaluation Ⅱ score and multiple organ dysfunction syndrome score in patients with severe pneumonia

Xin Mo1, Yanbing Liang2, Zhibin Chen2, Zhenyu Li2, Bingyu Yang1, Zhongfu Ma2,()   

  1. 1. Department of Neurology, the Third People's Hospital of Foshan, Foshan 528000, China
    2. Department of General Internal Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
  • Received:2015-11-19 Published:2016-06-01
  • Corresponding author: Zhongfu Ma
  • About author:
    Corresponding author: Ma Zhongfu, Email:
引用本文:

莫新, 梁艳冰, 陈志斌, 李振宇, 杨冰玉, 马中富. 重症肺炎患者血清胆碱酯酶含量变化及其与急性病生理学和长期健康评价Ⅱ评分、多器官功能障碍综合征评分的相关性研究[J/OL]. 中华危重症医学杂志(电子版), 2016, 09(03): 159-162.

Xin Mo, Yanbing Liang, Zhibin Chen, Zhenyu Li, Bingyu Yang, Zhongfu Ma. Correlation of serum cholinesterase and acute physiology and chronic health evaluation Ⅱ score and multiple organ dysfunction syndrome score in patients with severe pneumonia[J/OL]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2016, 09(03): 159-162.

目的

探讨重症肺炎患者血清胆碱酯酶(S-ChE)含量的变化及其与急性病生理学和长期健康评价Ⅱ(APACHEⅡ)评分、多器官功能障碍综合征(MODS)评分的相关性。

方法

选择重症肺炎患者86例(重症肺炎组),根据住院期间内是否死亡将研究对象分为存活组(46例)和死亡组(40例)。并同期选择普通肺炎患者100例(普通肺炎)及健康体检者124例(对照组)为对照。采集所有病例进入ICU后24 h内S-ChE水平,并计算其APACHEⅡ评分、MODS评分情况。采用Pearson相关分析对S-ChE水平与APACHEⅡ评分、MODS评分进行相关性研究。

结果

重症肺炎患者组的S-ChE含量为(3 679 ± 1 433)U/L,普通肺炎组为(5 142 ± 1 884)U/L,对照组为(8 469 ± 1 377)U/L,重症肺炎组的S-ChE含量明显低于普通肺炎组和对照组(P均<0.05)。重症肺炎患者死亡组的S-ChE含量明显低于存活组[(2 748 ± 826)U/L vs.(4 489 ± 1 360)U/L,t=7.041,P<0.001],而APACHEⅡ评分[(26 ± 5)分vs.(16 ± 5)分,t=8.540,P<0.001]、MODS评分[(8.15 ± 2.49)分vs.(4.35 ± 2.01)分,t=7.832,P<0.001]则分别明显高于存活组。同时,重症肺炎患者S-ChE含量与APACHEⅡ评分(r=-0.437,P<0.05)、MODS评分(r=-0.337,P<0.05)均存在显著负相关。

结论

重症肺炎患者的S-ChE含量明显降低,其高低能反映重症肺炎患者病情的轻重,并与APACHEⅡ评分、MODS评分呈负相关。

Objective

To observe the change of serum cholinesterase (S-ChE) levels in patients with severe pneumonia and its correlativity with acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ) score and multiple organ dysfunction syndrome (MODS) score.

Methods

A total of 86 patients with severe pneumonia were enrolled in this study as the severe pneumonia group, and divided into the survival group (46 cases) and death group (40 cases). And 100 patients with common pneumonia (common pneumonia group) and 124 people with health examination normal (control group) were served as control. The S-ChE levels were collected and APACHE Ⅱ score and MODS score were calculated after the patients were hospitalized in ICU within 24 hours. The Pearson correlation was used to analyze the association between S-ChE level and APACHE Ⅱ score as well as MODS score.

Results

The S-ChE levels in the severe pneumonia group, common pneumonia group and control group were (3 679 ± 1 433) U/L, (5 142 ± 1 884) U/L, (8 469 ± 1 377) U/L, respectively, and the S-ChE levels in the severe pneumonia group were much lower than those in the common pneumonia group and control group (all P<0.05). Meanwhile, the S-ChE levels in the death group [(2 748 ± 826) U/L vs. (4 489 ± 1 360) U/L, t=7.041, P<0.001] were much lower, whereas the APACHEⅡscores (26 ± 5 vs. 16 ± 5, t=8.540, P<0.001) and MODS scores (8.15 ± 2.49 vs. 4.35 ± 2.01, t=7.832, P<0.001) were higher than those in the survival group. The Pearson correlation showed that the S-ChE levels were negative related with APACHE Ⅱscore (r=-0.437, P<0.05) and MODS score (r=-0.337, P<0.05).

Conclusion

The S-ChE levels in patients with severe pneumonia decrease remarkedly, which can reflect the severity of severe pneumonia and have negative correlation with APACHE Ⅱscore or MODS score.

表1 三组肺炎患者S-ChE含量的比较(±s
表2 重症肺炎患者存活组与死亡组临床资料比较(±s
[1]
Mandell LA, Wunderink RG, Anzueto A, et al.Infectious Diseases Society of American/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adult[J].Clin Infect Dis, 2007 (44 Suppl 2): S27-S72.
[2]
Richard G, Levy H, Laterre PF, et al.CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS[J].J Intensive Care Med, 2011, 26 (1): 34-40.
[3]
田金飞,汤彦,向小卫,等.动态APACHE Ⅲ联合MODS评分在ICU临床研究中的应用[J].职业与健康,2011,27(4):370-372.
[4]
中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655.
[5]
王超,苏强,张淑文,等.多器官功能障碍综合征病情严重度评分系统[J].中国医学科学院学报,2007,29(4):497-500.
[6]
张细江.老年重症社区获得性肺炎患者血清胆碱酯酶的变化及意义[J].中国急救医学,2009,29(12):1081-1083.
[7]
Kanai S, Honda T, Uehara T, et al.Liver function tests In Patients with bacteremia[J].J Clin Lab Anal, 2008,22 (1): 66-69.
[8]
al-Kassab AS, Vijayakumar E.Profile of serum choline-sterase in systemic sepsis syndrome(septic shock) in intensive care unit patients[J].Eur J Clin Chem Clin Biochem, 1995, 33 (1): 11-14.
[9]
Wolkmer P, Lopes ST, Franciscato C, et al.Trypanosoma evansi: cholinesterase activity in acutely infected Wistar rats[J].Exp Parasitol, 2010, 125 (3): 251-255.
[10]
杨青茹,吴焱旻,张敬浩,等.老年重症肺炎血清胆碱酯酶、前白蛋白与预后[J].临床肺科杂志,2012,17(12):2194-2196.
[11]
刘金涛,王绍红,陈若冰.血清胆碱酯酶在危重症感染患者中的变化对其预后的探索[J].中国医学创新,2013,10(26):126-127.
[12]
刘进,王磊.胆碱酯酶对判断全身炎症反应综合征患者预后的价值[J].临床荟萃,2012,27(1):48-49.
[13]
张细江,何宗广.感染性休克患者血清胆碱酯酶的变化及临床意义[J].中国急救复苏与灾害医学杂志,2013,8(1):26-29.
[14]
卑源琪,陆俊国,陶勇,等.血清胆碱酯酶水平对脓毒症患者病情判断意义[J].交通医学,2013,27(6):658-659.
[15]
朱睿瑶,张迪,冯丽芝,等.血乳酸、胆碱脂酶与APACHEⅡ评分在评估危重症患者病情预后中的研究[J].医学研究杂志,2014,43(3):65-67.
[16]
Hsieh BC, Hsiao HY, Cheng TJ, et al. Assays for serum cholinesterase activity by capillary electrophoresis and an amperometric flow injection choline biosensor[J].Anal Chim Acta, 2008, 623 (2): 157-162.
[17]
陈文彬,潘祥林.诊断学[M].第8版.北京:人民卫生出版社,2013:398.
[18]
黄帆,杨静,仲飞,等.大面积脑梗死患者早期血清胆碱酯酶活性检测的临床意义[J].热带医学杂志,2008,8(10):1046-1048.
[19]
郑建琼,黄德斌.老年脓毒症患者血清清蛋白、D-二聚体及胆碱酯酶检测意义[J].中国老年学杂志,2014,34(13):3522-3523.
[20]
李艳华,张国荣,任连峰.多器官功能障碍障碍综合征的血清白蛋白及胆碱酯酶肌钙蛋白T水平的意义和预后的关系[J].河北医学,2013,19(4):490-492.
[21]
施新萍,楼利剑,娄域峰.肺部疾病引发全身炎症反应综合征的老年患者死亡因素分析[J/CD].中华危重症医学杂志:电子版,2011,4(1):26-30.
[1] 张烈, 严一核, 杜洁瑜. 分泌型白细胞蛋白酶抑制因子对无创呼吸机治疗重症肺炎患者的预测效能[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(04): 301-306.
[2] 李世杰, 申传安. 烧伤合并吸入性损伤患者呼吸机相关肺炎的研究现状[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(04): 351-355.
[3] 张胜伟, 孟召路, 热汗古丽·吾休尔, 万世森, 闫鹏, 阳乔. 肺炎支原体诱发反应性感染性皮疹黏膜疹一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 309-313.
[4] 郑宝英, 黄小兰, 贾楠, 朱春梅. 儿童难治性肺炎支原体肺炎早期预警指标[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 215-221.
[5] 徐保平, 彭怀文, 喻怀斌, 王晓涛. 新型冠状病毒肺炎继发糖尿病酮症酸中毒合并肝门静脉积气一例[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 250-255.
[6] 于燕兴, 梅喜庆, 刘凤娟, 于梓薇, 许亚慧, 徐飞. 高通量测序重症肺炎肺泡灌洗液病原体的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 785-788.
[7] 刘雯, 赵明栋, 夏伟, 潘以雄. 不同剂量比阿培南治疗重症肺炎的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 789-792.
[8] 刘春军, 严方方, 王宝锋, 常婷婷, 郭红红, 李志强. 替加环素联合人免疫球蛋白治疗XDRAB致VAP 的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 797-800.
[9] 胡菊英, 李银华, 洪兰, 王宏勇, 丁先军, 李承美, 谭心海. 儿童感染大叶性肺炎与支气管肺炎临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 813-816.
[10] 晏彦, 杨军, 周凤兰, 孙登昆, 陈玉. 哌拉西林他唑巴坦和哌拉西林舒巴坦治疗细菌性肺炎的倾向性匹配分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 817-819.
[11] 燕红玲, 王岩岩, 陈树斌. PCT、NLR联合LUBS预测ICU CRKP致呼吸机相关肺炎撤机及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 617-620.
[12] 张怡, 王宇洋, 司梦娇, 曹燕, 李欢欢. 脑卒中前白蛋白与肺炎发生风险相关性分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 648-651.
[13] 白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[14] 杨东星, 沈鹏, 赵慧颖. 免疫球蛋白联合依库珠单抗治疗GBS 并发重度ARDS 患者一例[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 404-408.
[15] 段伟, 刘飞, 许光源, 程宇豪, 陈星. 食管癌调强放疗计划剂量学参数差异对放射性肺炎发生及严重程度的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 320-324.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?